Insider Trading April 16, 2026 04:49 PM

Arteris COO Moll Laurent R. Sells 13,448 Shares for $269,380 Under 10b5-1 Plan

Transaction executed as stock trades near 52-week high after a 242% annual rise; company recently beat Q4 2025 revenue and EPS estimates

By Caleb Monroe AIP
Arteris COO Moll Laurent R. Sells 13,448 Shares for $269,380 Under 10b5-1 Plan
AIP

Arteris, Inc. Chief Operating Officer Moll Laurent R. disposed of 13,448 shares on April 14, 2026, generating roughly $269,380 in proceeds through sales priced between $19.90 and $20.22. The trade was carried out under a 10b5-1 plan adopted March 12, 2026, and was disclosed in a Form 4 filed with the SEC. The sale occurred while the company’s stock traded close to its 52-week high of $20.66 after a 242% gain over the past year. Arteris also reported fourth-quarter 2025 results that exceeded consensus revenue and EPS expectations.

Key Points

  • Arteris COO Moll Laurent R. sold 13,448 shares on April 14, 2026, for about $269,380 at prices between $19.90 and $20.22.
  • The sale was carried out under a 10b5-1 trading plan adopted March 12, 2026; after the transaction the COO directly owns 265,530 shares.
  • Arteris’s Q4 2025 results beat expectations with revenue of $20.1 million (vs. $18.55 million forecast) and EPS of -$0.05 (vs. -$0.07 expected); there are no recent M&A reports or analyst rating changes noted.

Transaction details

Arteris, Inc. (NASDAQ: AIP) Chief Operating Officer Moll Laurent R. sold 13,448 shares of the company’s common stock on April 14, 2026, realizing approximately $269,380. The executed share sales ranged in price from $19.90 to $20.22 per share, according to a Form 4 filed with the Securities and Exchange Commission.

The filing shows the disposition was made pursuant to a pre-arranged 10b5-1 trading plan that Moll Laurent R. adopted on March 12, 2026. After the April 14 transaction, Moll Laurent R. directly holds 265,530 shares of Arteris. The Form 4 was signed by Paul Alpern, acting as Attorney-in-Fact for Moll Laurent R., on April 16, 2026.


Market context

The stock sale took place while Arteris shares were trading close to a 52-week high of $20.66. The company’s share price has risen 242% over the past year, and the reported sales prices fell within a narrow band just below that high.


Recent company performance

Arteris reported fourth-quarter 2025 financial results that topped expectations. The company posted revenue of $20.1 million, ahead of the forecasted $18.55 million. Earnings per share for the quarter were reported at -$0.05, outperforming the expected -$0.07. Those figures are presented in the company’s reported results and indicate a quarter that exceeded consensus estimates on both top-line and per-share metrics.

Other disclosures

The filing and related disclosures note that there have been no recent reports of mergers or acquisitions involving Arteris, and there have been no recent analyst upgrades or downgrades reported in connection with the company. Beyond the transaction details and the quarter’s financial results, the public filings do not list additional related developments.


What this means for stakeholders

The reported sale was executed under a pre-arranged plan and was disclosed in accordance with SEC reporting requirements. The Form 4 indicates continued ownership by the executive following the sale. Investors and market participants can view the transaction alongside the company’s recent quarterly results when assessing Arteris’s current public profile.

Risks

  • The insider sale occurred while the stock traded near its 52-week high; investors monitoring equity performance and sentiment may view such transactions in the context of recent price appreciation.
  • Although the company beat Q4 2025 revenue and EPS estimates, future quarters could differ; reported results do not guarantee continued outperformance.
  • No recent analyst upgrades or downgrades and no reported M&A activity limit the availability of third-party catalysts or transactions that might materially affect near-term investor expectations.

More from Insider Trading

Astera Labs CEO Disposes $518K in Stock Under 10b5-1 Plan Apr 16, 2026 Forager Fund Reduces Stake in Regional Management, Selling $1.44M in Shares Apr 16, 2026 Aura Biosciences Legal Chief Sells Shares to Cover Taxes as Stock Trades Near Year High Apr 16, 2026 Pinterest Director Disposes $42,000 in Stock as Analysts Weigh In Apr 16, 2026 Gilead Executive Sells $422,880 in Stock as Company Advances HIV Access and AI Collaboration Apr 16, 2026